What is Insulet's revenue?

Insulet (PODD) generated $2.9B in revenue over the trailing twelve months, up 31.9% year over year.

Is Insulet profitable?

Insulet reported $302.8M in net income over the trailing twelve months, a 10.4% net margin.

What are Insulet's profit margins?

Gross margin is 71.0% and operating margin is 17.5%, with a 10.4% net margin.

What is Insulet's earnings per share?

Insulet's diluted EPS over the trailing twelve months is $4.29.

Where does Insulet's income statement data come from?

Every line is extracted from Insulet's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Insulet PODD Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$2.9B+31.9%	$2.71B+30.7%	$2.52B+27.1%	$2.36B+26.0%	$2.2B+23.5%
Total cost of revenue	$841M+29.2%	$768.2M+22.7%	$719.6M+18.4%	$690.2M+18.9%	$650.9M+17.4%
Gross profit	$2.06B+33.1%	$1.94B+34.2%	$1.8B+31.0%	$1.67B+29.2%	$1.55B+26.2%
Gross margin	71%+0.6pp	71.6%+1.8pp	71.5%+2.1pp	70.7%+1.7pp	70.4%+1.5pp
Research and development	$331.2M+44.6%	$301.1M+37.1%	$270.8M+34.7%	$248.5M+21.9%	$229M+11.7%
Selling, general and administrative	$1.22B+24.9%	$1.17B+27.0%	$1.09B+25.9%	$1.01B+24.3%	$978.2M+26.7%
Compensation and benefits	——	——	——	——	——
Depreciation and amortization	$94.9M+13.4%	$90.4M+11.9%	$87.5M+12.0%	$86.8M+15.0%	$83.7M+12.5%
Provision for credit losses	——	——	——	——	——
Other operating expenses	——	——	——	——	——
Operating income	$507.2M+48.9%	$473.9M+53.5%	$436.9M+42.8%	$407.3M+49.4%	$340.7M+36.7%
Operating margin	17.5%+2.0pp	17.5%+2.6pp	17.3%+1.9pp	17.3%+2.7pp	15.5%+1.5pp
Interest expense	$64.8M+57.3%	$59.3M+38.9%	$53M+29.9%	$49.8M+28.4%	$41.2M+9.9%
Interest income	$29.3M-27.5%	$34.7M-12.2%	$39.3M+11.0%	$41.2M+23.0%	$40.4M+28.3%
Other income (expense), net	$17.2M+332%	$14.3M+342%	$11.2M+380%	-$4.3M-4,400%	-$7.4M-535%
Gain (loss) on extinguishment of debt	-$84.4M-114%	-$123.9M—	-$123.9M—	-$123.9M—	-$39.5M—
Income before income taxes	$404.4M+37.7%	$339.6M+13.1%	$310.8M+4.7%	$270.9M+1.2%	$293.6M+19.8%
Income tax expense	$101.5M+185%	$92.3M+172%	$53.8M+143%	$24M+119%	-$119.4M-1,195%
Net income	$302.8M-24.7%	$247.1M-40.9%	$246.2M-41.5%	$236.1M-40.3%	$402.2M+71.9%
Net margin	10.4%-7.9pp	9.1%-11.1pp	9.8%-11.5pp	10%-11.1pp	18.3%+5.2pp
Diluted earnings per share	$4.29-22.7%	$3.49-39.6%	$3.44-41.4%	$3.28-40.7%	$5.55+66.7%
Basic earnings per share	$4.30-25.1%	$3.50-41.5%	$3.50-41.9%	$3.37-40.4%	$5.74+71.3%
Weighted-average shares, diluted	283.4M-4.2%	287.3M-2.7%	289.3M-2.0%	292.6M-0.7%	295.8M+1.6%
Weighted-average shares, basic	281.1M+0.2%	281.4M+0.4%	281.1M+0.4%	280.9M+0.5%	280.5M+0.5%
Litigation provision	——	——	——	——	——
Adjustments to Additional Paid In Capital, Purchase of Settlement Capped Call Transactions	——	——	——	——	——
Share-based compensation expense related to employee stock plans	——	——	——	——	——
Pre-tax stock-based compensation cost	——	——	——	——	——
Amortization Of Financing Costs And Discounts	$4.4M-43.6%	$6.2M-15.1%	$7.3M-2.7%	$8.1M+8.0%	$7.8M+8.3%
Stock options excluded as their inclusion would be anti-dilutive (in shares)	——	——	——	——	——
Capital investments accrued but not yet paid	——	——	——	——	——
Software amortization expense	——	——	——	——	——
Capitalized Contract Cost Amortization	——	——	——	——	——
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	——	——	——	——	——
Revenue recognized that was included in deferred income at the beginning of the period	——	——	——	——	——
Deferred and other income taxes	$66.2M—	$62.2M—	——	——	——
Effect of exchange rate changes on cash, cash equivalents and restricted cash	——	——	——	——	——
Effective tax rates	——	——	——	——	——
Accounts payable	——	——	——	——	——
Increase in accrued expenses and other liabilities	——	——	——	——	——
Increase (Decrease) in Inventories	——	——	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	$61.3M+78.7%	$81.7M+273%	$60.6M+76.2%	$37.8M-0.5%	$34.3M+51.1%
Incremental Common Shares Attributable To Conversion Of Debt Securities	——	——	——	——	——
After tax effect of debt interest	——	——	——	——	——
Amount awarded	——	——	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	-$1.19B—	-$595.3M—	-$543.6M—	-$88.5M—	——
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$234.8M-70.4%	-$222.7M-52.3%	-$137.9M-25.6%	-$136.2M-32.1%	-$137.8M-36.0%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$619.3M+52.4%	$569.3M+32.3%	$533.5M+62.7%	$516.1M+87.3%	$406.4M+74.6%
Number of operating segments	——	——	——	——	——
Number of reportable segments	——	——	——	——	——
Other comprehensive income/(loss) before reclassifications	——	——	——	——	——
Foreign currency translation	——	——	——	——	——
Tax on unrealized gain on derivative hedge agreements	——	——	——	——	——
Change in net unrealized gain (loss) on derivative instruments	——	——	——	——	——
Other comprehensive income/(loss)	——	——	——	——	——
Other income, net (Note 6)	$17.2M+332%	$14.3M+342%	$11.2M+380%	-$4.3M-4,400%	-$7.4M-535%
All other operating activities	$2.8M-67.4%	$7M+42.9%	$5M-24.2%	$4.3M—	$8.6M—
Payments for Repurchase of Common Stock	$359.6M—	$59.6M—	$59.6M—	$30.1M—	——
Payments for Software	——	——	——	——	——
Payment, Tax Withholding, Share-Based Payment Arrangement	$20.4M-14.3%	$25.9M+241%	$25.7M+262%	$24.4M+281%	$23.8M+250%
Payments to Acquire Property, Plant, and Equipment	$203.6M+76.9%	$191.6M+53.4%	$110.1M+9.4%	$111.2M+18.3%	$115.1M+32.0%
Net Proceeds from Issuance of Long-Term Debt	——	——	——	——	——
Settlement of capped call options	——	——	——	——	——
Cash received from option exercises	$16.9M+245%	$19M+132%	$17.7M+52.6%	$13.9M+27.5%	$4.9M-69.6%
Standard and Extended Product Warranty Accrual, Decrease for Payments	——	——	——	——	——
Product Warranty Accrual Warranties Issued	——	——	——	——	——
Net additions (releases) charged to costs and expenses	——	——	$4.3M+438%	$4.2M+367%	$3.2M+39.1%
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	——	——	——	——	——
Repayments Of Convertible Debt	$888.3M+442%	$1.05B—	$1.05B—	$541.5M—	$163.9M—
Repayments Of Other Long Term Debt	——	——	——	——	——
Repayments of Secured Debt	——	——	——	——	——
Restricted stock units vested, net of shares withheld for taxes	——	——	——	——	——
Stock-based compensation	$65.8M-10.2%	$62.7M-9.5%	$62.4M+0.6%	$63.8M+17.3%	$73.3M+45.1%
Stock Issued During Period, Value, Stock Options Exercised	——	——	——	——	——
Deferred compensation	——	——	——	——	——
Number of shares purchased (in shares)	——	——	——	——	——
Treasury stock, value, acquired	——	——	——	——	——
EBIT	$507.2M+48.9%	$473.9M+53.5%	$436.9M+42.8%	$407.3M+49.4%	$340.7M+36.7%
EBITDA	$602.1M+41.9%	$564.3M+44.8%	$524.4M+36.5%	$494.1M+41.9%	$424.4M+31.1%
EBITDA	$602.1M+41.9%	$564.3M+44.8%	$524.4M+36.5%	$494.1M+41.9%	$424.4M+31.1%
EBITDA margin	20.8%+1.5pp	20.8%+2.0pp	20.8%+1.4pp	20.9%+2.3pp	19.3%+1.1pp
EBIT	$507.2M+48.9%	$473.9M+53.5%	$436.9M+42.8%	$407.3M+49.4%	$340.7M+36.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Insulet.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Insulet's revenue?: Insulet (PODD) generated $2.9B in revenue over the trailing twelve months, up 31.9% year over year.
Is Insulet profitable?: Insulet reported $302.8M in net income over the trailing twelve months, a 10.4% net margin.
What are Insulet's profit margins?: Gross margin is 71.0% and operating margin is 17.5%, with a 10.4% net margin.
What is Insulet's earnings per share?: Insulet's diluted EPS over the trailing twelve months is $4.29.
Where does Insulet's income statement data come from?: Every line is extracted from Insulet's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.